Objectives: The aim of this study was to assess the predictive value of PMA measurement for mortality.
| INTRODUCTION
In the past decade transcatheter aortic valve implantation (TAVI) has evolved as a suitable treatment for patients with severe and symptomatic aortic valve stenosis (AS) with intermediate to high surgical risk. 1, 2 For TAVI planning and device selection, a computed tomography (CT) is routinely performed and covers the complete thorax and abdomen. In addition to its current use, CT can also be used to measure body composition. One of the most prominent shortcomings of current risk stratification models is an objective measure for frailty, which is associated with a lower quality of life and a higher risk of death after TAVI. 3, 4 Sarcopenia, which is defined as the loss of skeletal muscle mass and functioning due to ageing, is likely to reflect frailty, 4, 5 covering the biological age as it reflects a state of declined functional capacity and increased vulnerability to disease, disability and death. 6, 7 Psoas muscle area (PMA) is a validated surrogate for global muscle mass. 8 The in vivo-reference standard for measuring muscle mass, including PMA, is by CT scan. 4 Accordingly, in this study we examined ne the predictive value of PMA assessed with CT for all-cause and cardiac mortality at short-and long-term in patients who underwent a TAVI.
| METHODS

| Subjects
All 651 consecutive patients with severe AS who were treated with a TAVI between January 2010 and January 2016 in the Academic Medical Center (AMC, Amsterdam, The Netherlands) were identified.
All patients provided informed consent for the procedure. The institutional review board approved this study with a waiver. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
| CT scanning protocol
The CT angiography scans were acquired per protocol during the workup for the TAVI procedure using a 64-slice multi-detector scanner (Brilliance, Philips Medical Systems, Cleveland, OH) and a dual source 2 × 192 slice multi-detector scanner (Somatom Force, Siemens, Erlangen, Germany). For the 64-slice scanner, the CT angiography scan parameters were fixed: kV 120 and mAs 200. For the dualsource scanner, the CT angiography scan parameters were adjusted to patient characteristics derived from the topogram and timing bolus scan (care kV), reference kV 80 and quality reference mAs 178.
The contrast injection protocol and timing differed between the 64-slice and dual-source scanner. For both scanners intravenous contrast medium (300 mg Iodine/mL) and saline flush was injected at 5 mL/sec. For the 64-slice scanner bolus tracking was used. The CT angiography scan was initiated after injection of contrast (120 mL) followed by a saline flush (40 mL) using a region of interest in the ascending aorta and using an attenuation threshold of 125 Hounsfield Units (HU). For the dual-source scanner a timing bolus (contrast 10 mL, saline flush 40 mL) was used for timing the CT angiography acquisition (contrast 90 mL, saline flush 40 mL) using a region of interest in the ascending aorta.
| Psoas muscle assessment
The PMA was measured at vertebrae lumbar three (L3) 8 PMA of 25 random patients were double measured for intraobserver agreement. The same slice was also measured by a second observer for interobserver agreement.
| Data collection
Patient demographics, medical history, and procedural characteristics were collected from the prospective AMC TAVI registry.
| Outcome
The primary outcome of the study was all-cause and cardiac mortality.
Complete follow-up of mortality was collected through the Dutch national municipal population registry. Mortality rates were computed at 30 days, 1 year, and 2 years after TAVI. Cause of death was reported as cardiac or non-cardiac and was actively retrieved at the general practitioner or nursing home physician. Patients without clearly described cause of death were reported as cardiac mortality, all according to VARC2 criteria. Analyses were performed separately for males and females because of gender specific skeletal muscle mass differences. 13 Simple and multivariate Cox regression was used to determine the relationship between PMA and mortality. The added value of normalized PMA was examined by multivariable logistic regression correcting for STS-PROM and other confounders (age, peripheral artery disease, BMI, serum albumin, hemoglobin, chronic lung disease, estimated glomerular filtration rate, transfemoral/transthoracic access route).
3 | RESULTS
| Patient characteristics
Of the 651 patients undergoing a TAVI between January 2010 and January 2016, 583 were eligible for inclusion ( Figure 1 ). Table S1 ).
The median iPMA in males was 9. All-cause mortality at 30 days, 1 year, and 2 years in females was 3%, 13%, and 19%, respectively. In males, the all-cause mortality rate was 6%, 19%, and 29%, respectively.
| Primary outcome
Cox-regression HR for iPMA group and mortality, adjusted for STSscore and baseline characteristics for all-cause and cardiac mortality are presented in Table 2 .
In females, there was a significant protective effect of higher iPMA levels compared to the lowest tertile, especially for 1 year and 2 years cardiac mortality (Table 2) on cardiac mortality, but not in males (P = 0.53). All-cause and cardiac mortality for the entire population is presented in Supporting Information Table S2 .
| Comparison with STS-PROM and EuroSCORE II
In females, addition of the iPMA to current risk stratification models showed a modest improvement in the ability to predict 1-year Measuring iPMA is a part of determining sarcopenia. Sarcopenia is a component of frailty, which includes a degenerative loss of skeletal muscle mass and strength, possibly leading to adverse outcomes such as functional decline and death. 4 A CT scan prior to TAVI is routinely performed and PMA measures can be easily obtained. Furthermore, PMA can be measured with high reliability. 15, 16 In our study, we had nearly perfect intra-observer and intra-observer agreement. ) ; CABG, coronary artery bypass grafting; eGFR, estimated glomerular filtration rate; EuroSCORE, European system for cardiac operative risk evaluation; GOLD, global initiative for chronic obstructive lung disease; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; STS, society of thoracic surgeons; TAVI, transcatheter aortic valve implantation.
| Comparable literature
In multiple non-cardiac populations an association between PMA and all-cause mortality was demonstrated including in patients undergoing, for example, aortic aneurysm repair, 16 pneumonectomy, 17 and cancer surgery. 18, 19 All of them found a relation between low PMA and increased mortality rates, but gender specific reporting was lacking.
| Mortality
Previous studies investigating the association between PMA and mortality in TAVI patients revealed inconsistent results due to different time of follow-up and various methods of PMA measurement. To our knowledge, currently four studies investigated the relation between PMA and all-cause mortality in patients undergoing TAVI. 10, 15, 20, 21 The results of these studies are somewhat inconclusive. Firstly, Garg et al. found no significant association between PMA and 1 year mortality. 20 In contrast, Saji et al. found a significant association at 6 month. 10, 15, 20 Another study focused on both psoas volume and area and found the same result that the lowest tertile had a significant higher mortality compared to the other tertiles. 21 Mamane et al. have the only study investigating males and females separately. Similarly to this study, they found a significant difference in females, but it is unclear on what time interval. 10 Our current study includes to our knowledge, the largest study population of all currently available studies on this topic. All-cause mortality rate at 6 months was higher in other populations than in our study (21% vs. 10%), but can be ascribed to an earlier inclusion period with a corresponding higher mortality rate. Mortality rates were more comparable with our study sample at 30 days (5.9% vs. 5.4%) and 1 year (15.1% vs. 16.2%).
| Assessment of sarcopenia
Comparing results between studies remains difficult due to the incon- Second, there are differences in measuring PMA in the selected slices. Mamane et al. 10 and Saji et al. 15 both used density thresholds of −30-150 HU, comparable with our method. Mamane et al. 10 used a threshold brush tool. Garg et al. 20 outlined the psoas muscles (left and right) and computed the surface area based on the outline. By measuring the surface area on basis of the outline, these pixels are measured as muscle mass while the area consists of a combination of muscle mass, fat and connective tissue. 23 In our cohort, we detected considerable differences in the composition of the psoas muscle. A part of the patients had less and/or small pieces that were not selected by the used HU range, while other patients had much larger and/or more unselected pieces. It is known that during the ageing process, an increase in intramuscular adipose tissue and loss of muscle mass occurs. A smaller area and a changed composition may lead to a decline in strength and muscle quality. 23 Third, there are no validated cut-off values to define sarcopenia, but are merely based on the distribution in the studied population.
Cruz-Jentoft et al. 4 reported cut-off values for measuring muscle mass by determining all skeletal muscle masses in a whole cross sectional slice. Two studies classified as low, mid, and high, 10, 15 and one study only low and high. 20 Our study has a much larger sample size than the aforementioned studies and used the same low, mid and high groups, which allows for more reliable and stable estimates of the effect of iPMA on mortality.
| Study limitations
Despite the large sample size with negligible loss to follow-up and complete data for most variables, this study has some limitations.
First, this study was limited by its retrospective single center design with corresponding limitations. Second, because of the retrospective design it was not possible to investigate other aspects of sarcopenia or frailty including muscle strength (e.g., handgrip strength) and muscle performance (e.g., gait speed) 4 or factors influencing outcome such as antiaggregant/anticoagulant therapy. 
| CONCLUSIONS
In our study, a low iPMA is an independent predictor for cardiac and all-cause mortality at 1 year and 2 years follow-up in females. We conclude that the PMA measurements from routine preoperative imaging are likely of added value as objective tool in the prediction of mortality risks. We believe further studies should focus on automated and refined image analysis method to make body composition information easily available.
